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Abstract
QRS duration and morphology, evaluated via a standard 12-lead electrocardiogram (ECG),
represent an opportunity to derive useful prognostic information regarding the risk of subse-
quent cardiac events or therapeutic outcomes. Prolonged QRS duration, and the presence of
intraventricular conduction abnormalities, usually indicate the presence of changes in the
myocardium due to underlying heart disease.
Prolonged QRS duration is often associated with depressed ejection fraction or enlarged left
ventricular volumes, but several studies have demonstrated that this simple ECG measure
provides independent prognostic value, after adjusting for relevant clinical covariates.
Post-infarction patients with prolonged QRS duration have a significantly increased risk of
mortality, although data associating QRS prolongation specifically with sudden death is less
supportive. In non-ischemic cardiomyopathy, there is no evidence that QRS duration has
prognostic significance in predicting mortality or sudden death. Prolonged QRS duration, and
especially presence of left bundle branch block, seems to predict a benefit from cardiac
resynchronization therapy in both ischemic and non-ischemic cardiomyopathy patients.
Therefore, QRS duration and morphology should not only be considered a predictor of death or
sudden death in patients after myocardial infarction, and in those suspected of coronary artery
disease, but also  as a predictor of benefit from cardiac resynchronization therapy in patients
with heart failure, whether of an ischemic or non-ischemic origin. (Cardiol J 2011; 18, 1: 8–17)
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Introduction
QRS duration (QRSd) and morphology, evalu-
ated using a standard 12-lead electrocardiogram
(ECG), have always been considered important
prognostic markers, even in individuals without
structural heart disease.
The Manitoba study [1] consisted of a cohort
of 3,983 men with a mean age at entry of 30 years,
followed with regular examinations including ECG
from 1948. During the 30 year observation period,
70 cases of sudden death occurred in men without
previous clinical manifestations of heart disease.
Left bundle branch block (LBBB) was found to be
associated with a relative 13.8-fold increased risk
of sudden death in this cohort of healthy men.
Studies that are more relevant to everyday clini-
cal practice typically involve patients referred for
evaluation due to suspected coronary disease.
Schinkel et al. [2] analyzed a large cohort of 1,227
patients referred for dobutamine stress echocardio-
graphy to evaluate suspected myocardial ischemia.
9Andrew Brenyo, Wojciech Zaręba, Prognostic significance of QRS duration and morphology
www.cardiologyjournal.org
During a mean follow-up of more than four years,
they found that patients with QRS duration ≥ 120 ms
had twice the cardiac mortality as did patients with
QRS < 120 ms. Multivariate analysis adjusted for
age, gender, smoking, hypertension, diabetes, hyper-
cholesterolemia, ST segment depression, angina, and
abnormal stress echocardiogram showed that QRS
duration ≥ 120 ms was significantly associated with
mortality with a hazard ratio of 1.8.
In another similar study of 4,033 patients with
known or suspected coronary artery disease, El-
hendy et al. [3] also demonstrated that QRS pro-
longation was associated with increased mortality
after adjusting for relevant clinical covariates.
These large studies, and other smaller reports, in-
dicate that QRS duration and morphology is of ma-
jor prognostic importance even in individuals with-
out organic heart disease. Abnormal QRS duration
and morphology frequently identify subjects with
clinically undetected cardiac abnormalities and an
increased risk of mortality.
Post myocardial infarction population
The standard 12-lead ECG should always be
considered when performing risk stratification of
patients who have experienced myocardial infarc-
tion (MI). Heart rate, atrioventricular conduction,
fascicular block, bundle branch block (BBB) and the
degree of ST-segment deviation have all been
shown to influence survival after MI [4]. Most of
the early work (before the era of percutaneous
transluminal intervention [PCI]) focused on the
relationship between BBB and prognosis post MI.
Those early studies consistently associated the
presence of BBB with increased short- and long-
term mortality with estimates of 20–30% at one
year [5–7]. In more recent datasets, it has become
clear that specific quantification of the QRSd, and
not just the presence or absence of BBB (Table 1),
can provide more prognostic information, such as
the likelihood of 30 day mortality or sudden cardiac
death (SCD) post MI [8].
Abnormal intraventricular conduction has been
extensively examined as a risk stratification tool in
diverse cardiovascular disease (CVD) populations,
including patients with abnormal left ventricular
(LV) function, dyssynchrony and those at increased
risk of SCD. Most of this work has focused on pa-
tients with chronic CVD and will be discussed in
detail below. The prognostic significance of quanti-
tative QRS conduction post acute MI has been rel-
atively under-studied in comparison with these
more chronic forms of CVD.  Existing data is main-
ly derived from post-hoc analysis of multi-center
registries focusing on revascularization, with 30 day
all-cause mortality as a common endpoint.
Recently, Wong et al. [9] examined the rela-
tionship between QRSd and 30 day mortality post
MI in a prespecified post hoc analysis of the Hirulog
and Early Reperfusion or Occlusion (HERO)-2
trial. They examined QRSd at baseline and 60 min-
utes after fibrinolysis in over 12,000 patients. Only
patients with normal QRSd (< 125 ms) or RBBB at
both time points were included in the analysis. Pa-
tients who developed LBBB or QRS delay not meet-
ing the criteria for RBBB were excluded. Any pro-
longation of the QRS within this studied population
was associated with increased 30 day mortality, but
only in patients with anterior MI, and not with infe-
rior MI. In the anterior MI population, the authors
noted a 30–40% increase in 30 day mortality for
every 20 ms increase in the QRSd from baseline.
A similar relationship was found in the GUSTO-1 [8]
population with QRS prolongation within the nor-
mal range (100 vs 80 ms) post anterior MI carrying
the strongest association and greatest prognostic
significance for 30 day mortality (OR 1.55; 95% CI
1.43–1.68).
Shortcomings of this robust dataset include its
compilation prior to the current PCI era, and the
lack of data regarding the actual cause of death.
Recent efforts have sought to overcome these limi-
tations and describe the prognostic weight of QRS
prolongation, as well as specify the cause of death,
with particular attention paid to SCD. Bauer et al.
[10] prospectively analyzed 1,455 survivors of acute
MI aged 75 or under with a dichotomized QRS vari-
able cutoff of 120 ms, and found a strong associa-
tion of QRS prolongation with total mortality (HR
4.0; 95% CI 2.3–6.9 after multivariate analysis).
However, the authors did not find a significant as-
sociation with SCD. A decreased incidence of BBB
was found in patients in this population when com-
pared to studies performed in the pre-PCI era (6 vs
10–20%) but with similar one year all-cause mor-
tality (18.6 vs 20.8%) [5]. The study pointed towards
patients with abnormal QRSd carrying higher post
MI mortality, but not from SCD. In another study
by Guerrero et al. [11], analyses of 3,053 post-inf-
arction patients who underwent primary angioplasty
showed that LBBB was associated with five-fold
higher in-hospital mortality; the authors did not
report prognostic value of QRS duration.
In an effort to assess the efficacy of treatment
with valsartan and captopril, and their combination,
in high-risk patients after MI (The Valsartan In
Acute Myocardial Infarction [VALIANT] trial [12])
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the authors included QRS duration as a prespeci-
fied subgroup. The primary outcomes included all-
cause and cardiovascular mortality as well as SCD
events. Patients with QRS prolongation were found
to have increased ventricular volumes, decreased
left ventricular ejection fraction (LVEF), and a high-
er incidence of heart failure (HF), cardiovascular
death and SCD. As observed in the HERO-2 and
GUSTO-1 trials, the increased risk was seen even
with QRS prolongation within the normal range.
Subsequent work by Solomon et al. [13] with the
VALIANT cohort found that risk of sudden death
within 30 days of MI was highest in patients with
an abnormal LVEF, which in the primary study cor-
related strongly with QRSd. This conclusion rein-
forces the belief that QRSd is an indicator of the bur-
den of CVD and probably carries with it an increased
risk of SCD post MI.
There is some inconsistency in the conclusions
of the aforementioned studies examining the risk
of SCD post MI with abnormal QRSd. Most of the
literature supports an increased risk of all-cause
mortality at 30 days, and at longer follow-up, regard-
less of the method of revascularization used to treat
the acute infarction. Why, then, should different
conclusions be drawn about the prognostic value of
QRSd for SCD events? The probable reason is that
there is a good deal of inconsistency between these
studies, particularly when the patient population is
considered. VALIANT enrolled patients who were
post MI with abnormal LVEF, while Bauer’s study
[10] took all comers with MI who were in normal
sinus rhythm. The population with abnormal QRSd
in the Bauer study [10], felt to be disproportionably
sicker than the population with normal intraventric-
ular conduction, had baseline characteristics almost
identical to the entire VALIANT population. This
suggests that the VALIANT patients with abnor-
mal QRSd have an increased burden of cardiovas-
cular illness and worse ventricular function when
compared to Bauer’s population with abnormal
QRSd. This is, in fact, the case and probably serves
to identify a population within the VALIANT cohort
that is at a higher baseline risk of SCD than the
Bauer population. These study population differenc-
es act to explain the prognostic value for abnormal
QRSd within the VALIANT population and not the
Bauer population. Abnormal QRSd is, at least, a risk
for all-cause mortality at both 30 days and later, and
is also probably prognostic of SCD events, although
the data is currently inconclusive.
With the prognostic relationship of QRSd post
MI probably carrying an increased risk of death and
SCD post MI, the next question is whether or not
it should be used in guiding antiarrhythmic thera-
py during this vulnerable time. The DINAMIT [14]
trial primarily examined the efficacy of implantable
cardioverter-defibrillator (ICD) placement in pa-
tients 6–40 days post MI with abnormal LVEF,
along with impaired cardiac autonomic function (de-
pressed HR variability or elevated 24-hour HR on
Holter monitoring), but also stratified the patients
by QRSd as a prespecified subgroup. On the whole,
the trial did not show any mortality benefit for ICD
placement, but it did display a non-significant trend
towards benefit for ICD placement in patients with
prolongation of the QRS beyond 120 ms. The au-
thors noted that arrhythmic death was significant-
ly decreased, with a similar increase in nonarrhyth-
mic death, resulting in no all-cause mortality bene-
fit for ICD implantation within this population.
It is as yet unclear whether prolongation of the
QRS complex post acute MI poses an independent
risk for SCD. Abnormal QRS duration is prognos-
tic of increased short-term [8, 9] and long-term [5,
10] all-cause mortality probably secondary to the
higher burden of CVD within this population. The
question of what to do with this information beyond
standard post MI aggressive medical therapy re-
mains unanswered.
Ischemic cardiomyopathy
Abnormal intraventricular conduction has been
examined extensively as a risk factor for overall
mortality, as well as SCD, in patients with ische-
mic cardiomyopathy (ICM) (Table 2). Earlier stud-
ies such as the CASS trial [15] established abnor-
mal intraventricular conduction in patients with
ICM as an independent risk factor for all-cause
mortality, particularly for LBBB. The limitations of
this data are that it was compiled prior to the cur-
rent revascularization era and did not specifically
address arrhythmic death.
Current understanding of the relationship be-
tween QRS prolongation and risk of SCD in the ICM
population has resulted from secondary analyses of
multi-center defibrillator databases such as MUSTT
and MADIT-II. Although this data is robust, the
magnitude of the relationship between abnormal
intraventricular conduction and SCD in the ICM
population, along with its clinical utility, remains
unclear.
In their analysis of the MUSTT population,
Zimetbaum et al. [16] examined the relationship
between numerous ECG abnormalities and all-
cause mortality/SCD in patients who were not treat-
ed with antiarrhythmic therapy (antiarrhythmic
12
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medication or ICD implantation). The ECG abnor-
malities included: intraventricular conduction de-
lay (IVCD), LBBB, RBBB, left ventricular hyper-
trophy, and left atrial hypertrophy, with the rele-
vant endpoints being arrhythmic death and all-cause
mortality. After multivariate adjustment, only IVCD
(HR 1.44), and LBBB (HR 1.49) were associated
with arrhythmic death and all-cause mortality. The
increase in total mortality associated with LBBB or
IVCD, however, outweighed the increase in ar-
rhythmic death risk, suggesting a lack of cause and
effect between conduction abnormalities and death.
The authors noted that patients with LBBB or IVCD
had lower ejection fractions and a higher incidence
of symptomatic HF than those without, suggesting
that the increase in overall mortality was probably
due to a sicker LBBB and IVCD population. These
results seem to mesh well with previous data from
the CASS registry that displayed increased all-cause
mortality associated with LBBB, but not with RBBB,
in patients with ischemic heart disease [15].
While the sub-analysis of CASS and MUSTT
dealt primarily with medically managed patients
with HF, the question of whether or not patients
with ICM and abnormal intraventricular conduction
were more likely to benefit from ICD placement due
to aborted SCD remained. In an initial analysis of
both SCD-HEFT and MADIT-II, a greater baseline
prolongation of QRS was associated with a trend
toward increased benefit from ICD implantation [17,
18]. This association, although present, was not sig-
nificant in either study.
A subsequent analysis of 431 patients in the
PainFREE II study did not display any association
between QRS duration and ventricular tachycardia
(VT)/ventricular fibrillation (VF) in ICD treated
patients [19]. Dhar et al. [20] performed an analy-
sis of 731 patients from the MADIT-II cohort with
prolonged QRSd, and found it to be an independent
predictor of SCD in medically managed patients (HR
2.12) but not in ICD-treated patients (HR 0.77). This
is not surprising, because the ICD-treated MADIT II
patients died predominantly of non-sudden HF, and
QRSd would not be expected to predict HF mortality.
At the same time, VT/VF is much more common
than SCD, indicating that many ventricular arrhyth-
mias terminate spontaneously. The MADIT-II sub-
study treated QRSd as a continuous variable, while
other studies have utilized an inconsistent cutoff
value to determine if QRSd is abnormal. This dif-
ference, along with the near identical patient popu-
lations (ICD and non-ICD groups), allowed the au-
thors to display a consistent association of length-
ened QRSd and SCD across the spectrum of QRSd,
as well as determining the prognostic significance
of abnormal intraventricular conduction within
these two groups.
More recently, QRSd has been used as a strat-
ification tool for arrhythmic risk in patients post
ICD placement within the MADIT II cohort [21].
Amongst other basic clinical factors, it was found
to have a significant association with events, car-
rying a HR of 1.56. The model already has been
validated, indicating the importance of QRSd among
other variables composing MADIT II score [22].
Non-ischemic cardiomyopathy
Compared to the ICM population, there is lit-
tle data examining the relationship between QRSd
and SCD/VF events in the non-ischemic cardiomyo-
pathy (NICM) population (Table 3). Our current un-
derstanding of the prognostic implications of abnor-
mal QRSd within the NICM population is the result
of subgroup analyses of large multi-center defibril-
lator efficacy trials, similar to the ICM population.
The major exception to this is the Marburg
Cardiomyopathy study (MACAS), a kind of ‘natural
history’ cohort study of NICM patients that exam-
ined the prognostic implications of baseline patient
characteristics in relation to outcomes. Previous
small studies had shown that an abnormal signal av-
eraged ECG has prognostic value in predicting ven-
tricular arrhythmias and sudden deaths within the
NICM population [23, 24]. However, standard 12-
lead ECG is the principal source of information re-
garding QRS duration and morphology.
In MACAS [25], a cohort of 343 NICM patients
were followed clinically for the development of ar-
rhythmic events with baseline variables obtained
including QRSd and morphology. Neither LBBB nor
RBBB predicted arrhythmic events within this co-
hort. The only baseline characteristic that was pre-
dictive of VF/SCD events was enrollment LVEF
(RR of 2.3 for every 10% decrease in ejection frac-
tion). Although MACAS was observational in na-
ture, it provided excellent information regarding the
natural history of NICM and cast doubt upon the
predictive utility of QRSd for VF/SCD events.
Subsequent to the findings of MACAS, the
DEFINITE trial [26] enrolled patients with idio-
pathic dilated cardiomyopathy and either premature
ventricular complexes or non-sustained ventricu-
lar tachycardia on 24-hour Holter monitoring and
randomized them to either ICD placement or stan-
dard medical therapy. Within this population, they
found that ICD treatment resulted in an absolute
decrease in mortality over standard therapy of 7%
14
Cardiology Journal 2011, Vol. 18, No. 1
www.cardiologyjournal.org
at two years (14.1 vs 7.9%). This difference was not,
however, found to be statistically significant. QRSd
was a prespecified subgroup within the study with
a QRSd of 120 ms as their dichotomous cutoff point.
A trend toward benefit of ICD therapy in patients
with a QRSd longer than 120 ms was seen, but again
did not reach statistical significance. This should not
cause surprise, because the overall DEFINITE tri-
al had limited statistical power and so subgroup
analyses were even further underpowered. The
shortcomings of this data include the fact that QRSd
was treated as a dichotomous variable without spec-
ification for morphology or BBB. Previous studies
in an ischemic population showed that LBBB pa-
tients are at higher risk of arrhythmic death than
those with RBBB [15]. Regardless of the shortco-
mings of this data, it indicates that QRS duration
does not have prognostic significance in predicting
SCD/VF in the NICM population.
SCD-HEFT [17] is the largest randomized clini-
cal trial so far to assess the efficacy of ICD treatment
in the NICM population. Its design randomized
1,100 NICM and 1,400 ICM patients to receive ami-
odarone, ICD or placebo treatment. As a predefined
subgroup of this population, the patients were strat-
ified based upon a dichotomous QRS cutoff of 120 ms,
but without further stratification into ischemic vs
non-ischemic etiologies of LV dysfunction. The
group as a whole did display a non-significant trend
towards benefit of ICD placement if the QRSd was
longer than 120 ms, with the specificity of this re-
sult for the NICM population still in question. This
finding is consistent with the results of MACAS and
the DEFINITE subgroup that did not support abnor-
mal QRSd as having a prognostic role for SCD events.
With our current shortcomings regarding risk
stratification for SCD in both the ICM and NICM
populations, imaging, or more specifically cardiac
magnetic resonanse imaging (MRI), has been seen
as a possible tool to better identify patients at risk.
Hombach et al. [27] examined the utility of cardiac
MRI in conjunction with QRSd and QTc in predict-
ing SCD and cardiac death. Of the 149 patients en-
rolled, 94 had a QRSd of > 110 ms with a statisti-
cally significant HR of 5.43 for the primary endpoint.
QRSd, along with diabetes, cardiac index and right
ventricular end-diastolic volume index on cardiac
MRI, was significantly associated with the primary
endpoint in Hombach’s NICM cohort.
Overall, the current data indicates a lack of
predictive value of QRSd for SCD events in the
NICM population. This conclusion rests on sub-
group analysis of ICD efficacy trials either specifi-
cally designed for, or that just happened to include,Ta
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patients with NICM. These trials are smaller than
those that have examined the same question in the
ICM population. No trial involving a NICM popula-
tion has treated QRSd as a continuous variable, or
differentiated patients with QRS prolongation into
BBB subgroups.
QRSd appears to be a better indicator of the
overall burden of CVD, and less of an independent
predictor of SCD, within the NICM population.
QRS duration and morphology in cardiac
resynchronization therapy patients
Cardiac resynchronization therapy (CRT)
is indicated in HF patients with prolonged QRSd
(≥ 120 ms) [28–32]. The criterion of wide QRS com-
plex, qualifying HF patients for CRT, indicates that
a delay in intraventricular conduction is associated
with delayed activation of certain regions of the
heart and impaired dysynchronous contraction.
Applying LV or biventricular pacing in such patients
improves electrical activation of the ventricles and
improves contractility by synchronizing movements
of the LV free wall and interventricular septum.
Previous studies have documented that prolonged
QRSd, especially if associated with a LBBB, is as-
sociated with more advanced LV dysfunction in HF
patients. However, the prognostic significance of
BBB in HF patients remains controversial. Baldas-
seroni et al. [33] evaluated the prognostic signifi-
cance of QRS morphology in 5,517 HF outpatients,
with LBBB proving to be predictive of all-cause
mortality when compared to patients without
LBBB. Barsheshet et al. [34] evaluated 4,102 hos-
pitalized HF patients. RBBB, but not LBBB, was
found to be predictive for mortality. Differences in
clinical characteristics of studied patients probably
contribute to these differences.
The prognostic significance of QRS morpholo-
gy has been evaluated in several CRT trials. In the
Comparison of Medical Therapy, Pacing, and
Defibrillation in Heart Failure (COMPANION) trial
[28] enrolling class III and IV HF patients, there was
no significant difference in the risk of primary or
secondary endpoints between patients with LBBB
and patients with RBBB or IVCD. In the study by
Iler et al. [35] of 337 CRT patients, LBBB was not
predictive of death or heart transplant outcome. In
another cohort of 636 CRT patients  [36], three-year
average survival was significantly better in LBBB
than in RBBB patients. In a study by Wokhlu et al.
[37] of 505 CRT patients, survival over a median
2.6 years of follow-up was significantly better in
LBBB than in RBBB patients receiving CRT. These
observations indicate that a therapy, in this case
CRT, might modify the prognostic significance of
QRS morphology: LBBB patients seem to benefit
more from CRT than RBBB patients, and therefore
have better survival.
The MADIT-CRT [38] (Multicenter Automatic
Defibrillator Implantation Trial-Cardiac Resynchro-
nization Therapy) evaluated the effects of CRT-D vs
ICD-only therapy in 1,820 mild to moderate HF pa-
tients with ischemic (NYHA class I or II) and non-
ischemic (class II) cardiomyopathy with ejection
fraction £ 30% and QRS ≥ 130 ms. The CRT-D
therapy was associated with a 34% reduction in the
risk of primary endpoint, defined as death from any
cause or a non-fatal HF event (whichever came
first). Patients with QRS duration ≥ 150 ms derived
significantly more benefit from CRT-D than did pa-
tients with QRS < 150 ms. The LBBB patients
demonstrated the most significant effect of resyn-
chronization therapy in terms of reduction of HF
progression, whereas no such benefit was observed
in the RBBB and IVCD patients [39].
The MADIT-CRT trial provided evidence that
CRT very dramatically reduces the progression of
HF in relatively asymptomatic or mildly symptom-
atic patients with a low ejection fraction and wide
QRS complex. Similarly, in recently reported re-
sults of extended follow-up from the REVERSE trial
[40] that studied patients with HF in NYHA class I
or II with QRS ≥ 120 ms, the authors found that
patients with QRSd ≥ 152 ms tended to derive more
benefit from CRT (measured by composite HF sta-
tus) than patients with a QRS shorter than 152 ms.
The results of the Resynchronization/Defibril-
lation in Advance Heart Failure Trial (RAFT) pro-
vide further evidence for the importance of wide
QRS complex and LBBB morphology [41]. RAFT
enrolled 1,798 NYHA class II or III HF patients with
an ejection fraction £ 30% and an intrinsic QRS
≥ 120 ms or a paced QRS ≥ 200 ms, and randomi-
zed them to an ICD or CRT-D. The risk of primary
endpoint (HF hospitalization or death) was signifi-
cantly reduced, by 25% (HR 0.75; p < 0.001).
Patients with wide QRS benefited from CRT-D
therapy significantly more than patients with QRS
< 150 ms and patients with LBBB benefited more
from CRT-D than patients with RBBB, IVCD or
paced QRS. RAFT also showed a significant de-
crease in mortality, which was significantly higher
than in MADIT-CRT [42].
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Summary
QRS duration and morphology should be con-
sidered as important prognostic information indicat-
ing more advanced cardiac pathology secondary to
underlying heart disease, whether that heart dis-
ease is known about or not. Post-infarction patients
with prolonged QRSd have a significantly increased
risk of mortality, although data associating QRS
prolongation specifically with sudden death is less
supportive. In NICM, there is no evidence that
QRSd carries prognostic significance for predicting
mortality or sudden death. However, cohorts of
patients with HF and low ejection fraction usually
include about 50% of patients with NICM; in such
studies, a significantly prolonged QRSd, and espe-
cially the presence of LBBB, seem to predict bene-
fit from CRT-D therapy in both ICM and NICM
patients [43]. Therefore, QRS duration and mor-
phology should not only be considered as a predic-
tor of death or sudden death, but also as a predictor
of benefit from CRT in patients with HF, whether
of ischemic or non-ischemic origin.
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